JP2023098947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023098947A5 JP2023098947A5 JP2023061595A JP2023061595A JP2023098947A5 JP 2023098947 A5 JP2023098947 A5 JP 2023098947A5 JP 2023061595 A JP2023061595 A JP 2023061595A JP 2023061595 A JP2023061595 A JP 2023061595A JP 2023098947 A5 JP2023098947 A5 JP 2023098947A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antagonist
- composition
- fibrosis
- senescent cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 17
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 10
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 230000000798 anti-retroviral effect Effects 0.000 claims 1
- 229940124522 antiretrovirals Drugs 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382417.8 | 2017-06-29 | ||
| EP17382417.8A EP3421607A1 (en) | 2017-06-29 | 2017-06-29 | Identification and elimination of damaged and/or senescent cells |
| JP2019572038A JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Division JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023098947A JP2023098947A (ja) | 2023-07-11 |
| JP2023098947A5 true JP2023098947A5 (enExample) | 2024-03-25 |
Family
ID=59315550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Pending JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
| JP2023061595A Pending JP2023098947A (ja) | 2017-06-29 | 2023-04-05 | 損傷および／または老化細胞の同定および排除 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Pending JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200123607A1 (enExample) |
| EP (2) | EP3421607A1 (enExample) |
| JP (2) | JP2020525021A (enExample) |
| CA (1) | CA3068363A1 (enExample) |
| WO (1) | WO2019002581A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
| CA3108949A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| WO2021163369A2 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| US12024545B2 (en) * | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4431102A4 (en) * | 2021-11-10 | 2025-10-29 | Lifeceutix Co Ltd | Senescent Cell Elimination Compositions and Their Uses |
| CN114836508A (zh) * | 2021-12-08 | 2022-08-02 | 上海锐翌医学检验实验室有限公司 | 慢性阻塞性肺病标志微生物及其应用 |
| KR20240155337A (ko) | 2022-03-04 | 2024-10-28 | 리주베론 세네센스 테라퓨틱스 아게 | 항-pd-l2 항체 |
| JPWO2023238845A1 (enExample) * | 2022-06-07 | 2023-12-14 | ||
| CN115154611B (zh) * | 2022-06-23 | 2023-11-17 | 中山大学孙逸仙纪念医院 | 免疫检查点抑制剂与抗衰老药物联合在制备肿瘤治疗产品中的用途 |
| WO2024063109A1 (ja) * | 2022-09-20 | 2024-03-28 | 国立大学法人東京大学 | 老化細胞除去剤 |
| WO2024228599A1 (ko) * | 2023-05-04 | 2024-11-07 | 주식회사 라이프신약 | 노화세포 제거 또는 억제용 조성물 및 이의 용도 |
| WO2024249938A1 (en) * | 2023-05-31 | 2024-12-05 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating senescence/age-related diseases |
| WO2025051889A1 (en) * | 2023-09-06 | 2025-03-13 | Rejuveron Senescence Therapeutics Ag | Anti pd-l2 antibodies for use in treating fibrotic diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU2005248958A1 (en) * | 2000-06-28 | 2006-02-02 | Brigham And Women's Hospital | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| US20020164600A1 (en) * | 2000-06-28 | 2002-11-07 | Gordon Freeman | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| JP2017508785A (ja) * | 2014-02-04 | 2017-03-30 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ |
| WO2016134416A1 (en) * | 2015-02-23 | 2016-09-01 | The University Of Queensland | A method for assessing prognosis of lymphoma |
| WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| CN107847598B (zh) * | 2015-06-24 | 2022-01-25 | 英摩杜伦治疗学公司 | 用于癌症治疗的检查点抑制剂和全细胞分枝杆菌 |
| JP6949009B2 (ja) * | 2015-09-21 | 2021-10-13 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ヒトプログラム死リガンド２（ｐｄ−ｌ２）に結合する抗体およびその用途 |
-
2017
- 2017-06-29 EP EP17382417.8A patent/EP3421607A1/en not_active Withdrawn
-
2018
- 2018-06-29 JP JP2019572038A patent/JP2020525021A/ja active Pending
- 2018-06-29 CA CA3068363A patent/CA3068363A1/en active Pending
- 2018-06-29 WO PCT/EP2018/067655 patent/WO2019002581A1/en not_active Ceased
- 2018-06-29 EP EP18735568.0A patent/EP3645746A1/en active Pending
- 2018-06-29 US US16/627,034 patent/US20200123607A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061595A patent/JP2023098947A/ja active Pending
-
2024
- 2024-06-21 US US18/750,834 patent/US20240344128A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023098947A5 (enExample) | ||
| Galsky et al. | Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer | |
| AU2018288060B2 (en) | IL-1beta binding antibodies for use in treating cancer | |
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP2017522307A5 (enExample) | ||
| JP7142200B2 (ja) | ＭＡｄＣＡＭアンタゴニストの投与レジメン | |
| JP2017537090A5 (enExample) | ||
| Kuwana et al. | Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease | |
| JP2014533279A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2020511408A5 (enExample) | ||
| JP2019533651A5 (enExample) | ||
| JP2019525948A5 (enExample) | ||
| JP2014532648A5 (enExample) | ||
| WO2017165742A1 (en) | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments | |
| KR20230098279A (ko) | Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합 | |
| JP2017527615A5 (enExample) | ||
| Novello et al. | Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study | |
| CA3201519A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| Maxwell et al. | Drug-induced heart failure | |
| De Boer et al. | Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer | |
| JP7699613B2 (ja) | ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| Lim et al. | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |